Apremilast

General Information

Apremilast Impurities and Apremilast 

Daicel Pharma synthesizes high-quality Apremilast impurities, including Apremi+C39:C41 Last Impurity RS-9, Apremilast 2-Acetamido Benzoic Acid Impurity, Apremilast 3-Acetamido Benzoic Acid Impurity, Apremilast Amino Sulfone Impurity, Apremilast Des Acetyl 4-Desmethyl Impurity, Apremilast Impurity RS-7, and O-Desmethyl Apremilast. These impurities are essential for evaluating the quality, stability, and safety of Apremilast, which is an active pharmaceutical ingredient. Additionally, Daicel Pharma offers a customized synthesis of Apremilast impurities for global delivery to meet the specific needs of our customers.

Apremilast [CAS: 608141-41-9] is a medication to treat active psoriatic arthritis. It is an orally available small molecule that acts as an inhibitor of phosphodiesterase-4 (PDE-4) and an immunomodulating agent.

Apremilast: Use and Commercial Availability  

Apremilast, available under the brand name Otezla, is an FDA-approved medication for treating psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behcet disease in adults. Apremilast is the first and only FDA-approved oral medication for treating oral ulcers associated with Behcet disease.

Apremilast Structure and Mechanism of Action

The chemical name of Apremilast is N-[2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide. Its chemical formula is C₂₂H₂₄N₂O₇S, and its molecular weight is approximately 460.5 g/mol.

Apremilast inhibits phosphodiesterase 4 (PDE4), causing an increase in intracellular cyclic adenosine monophosphate (cAMP) levels.

Apremilast Impurities and Synthesis

Apremilast may contain impurities formed during the manufacturing¹ or storage of the drug. These impurities can be related to the starting materials, intermediates, or the final product. The impurities in a drug can affect its safety, efficacy, and quality, which is why it is necessary to identify and quantify them. Impurities in Apremilast can form due to several factors, such as degradation of the active pharmaceutical ingredient (API) or excipients, interaction with packaging materials, exposure to moisture or light, or incomplete chemical reactions during manufacturing. It is essential to synthesize and analyze the API and its impurities to ensure its quality, safety, and efficacy.

Daicel Pharma offers a Certificate of Analysis (CoA) for Apremilast impurity standards, which includes Apremi+C39:C41 Last Impurity RS-9, Apremilast 2-Acetamido Benzoic Acid Impurity, Apremilast 3-Acetamido Benzoic Acid Impurity, Apremilast Amino Sulfone Impurity, Apremilast Des Acetyl 4-Desmethyl Impurity, Apremilast Impurity RS-7, and O-Desmethyl Apremilast. The CoA is produced from a cGMP-compliant analytical facility and includes comprehensive characterization data, such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity². Additional characterization data, such as 13C-DEPT and CHN, can also be provided on request. Daicel Pharma can create unknown Apremilast impurities or degradation products and supply labeled compounds to evaluate the effectiveness of Apremilast. Further, Daicel Pharma offers Apremilast-D3, a deuterium-labeled Apremilast standard, useful in bio-analytical research, such as BA/BE studies. Each delivery has a complete characterization report.